# GLOW Peptide Research: Mechanisms of GHK-Cu, BPC-157, and TB-500 | MedsGLOW > GLOW peptide constituent research: GHK-Cu gene expression modulation, BPC-157 VEGFR2 angiogenesis, TB-500 G-actin sequestration. Cited peer-reviewed findings on each compound. ## Evidence Base for GLOW Peptide Constituents GLOW peptide constituent research spans three independent literature corpora. Each compound has distinct mechanisms, distinct study populations, and distinct evidence quality. The combined blend as formulated has not been tested in a controlled trial; all evidence below refers to individual constituents. Strength of evidence by constituent: GHK-Cu has multiple human cosmetic trials (topical formulations in photoaged skin); BPC-157 has a large preclinical base (primarily rodent, mostly from one research group) and limited human pilot data; TB-500 has moderate preclinical data and one ongoing human cardiac trial. ## GHK-Cu Anti-Aging Research: What the Studies Actually Show GHK-Cu is a tripeptide (glycyl-L-histidyl-L-lysine) that chelates copper. It naturally occurs in human plasma, declines with age (approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [17]), and has been the subject of sustained research by Loren Pickart and colleagues since the 1970s. **Gene expression scope.** In human gene expression analysis using the Connectivity Map, GHK-Cu modulated approximately 31.2% of all human genes at a 50% change threshold: 59% upregulated, 41% suppressed [1]. Regulated gene sets include collagen synthesis, MMP/TIMP balance, antioxidant networks (16 genes), fibrinogen suppression, and neurotrophic factor upregulation. A separate analysis of neurology-relevant genes found GHK upregulated 408 neuron-related genes and enhanced 47 DNA repair genes while suppressing inflammatory markers including TNF and IL17A [18]. **Collagen synthesis in fibroblasts.** GHK-Cu stimulated collagen synthesis in cultured human dermal fibroblasts at concentrations starting at 10^-12 M, with maximum effect at 10^-9 M, independent of changes in cell number [3]. The GHK sequence appears within the type I collagen alpha-2 chain, suggesting a possible in situ wound-signaling role. **ECM remodeling balance.** GHK-Cu stimulated MMP-2 expression via elevated mRNA in dermal fibroblasts while simultaneously enhancing TIMP-1 and TIMP-2 — indicating balanced ECM remodeling rather than unchecked matrix degradation [4]. **Human photoaged skin trial.** Twelve-week topical application of a GHK-Cu facial cream to 71 women with photoaged skin produced increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and wrinkle depth [2]. **Age-reversal in fibroblasts.** In a 2024 study, GHK supplementation in aged lung fibroblasts reversed senescence markers p21 and p53, restored fibroblast migration capacity, and facilitated apoptosis of excess myofibroblasts via integrin-beta-1 signaling — proposing GHK as a candidate for fibrosis interventions [17]. **Safety at research concentrations.** GHK-Cu was not cytotoxic and did not induce significant skin irritation biomarker expression at study concentrations in preclinical skin models, supporting low irritation potential [19]. ## GHK-Cu Copper Peptide and Skin Research GHK-Cu's documented effects on dermal tissue fall into two categories: collagen and ECM remodeling, and anti-senescence activity. Collagen remodeling: the compound upregulates COL1A1 and COL3A1 (structural collagens), MMP-2 (collagen-degrading remodeling enzyme), and the inhibitory TIMPs in a balanced equilibrium [1, 4]. The clinical translation in photoaged skin (n=71, 12 weeks) showed measurable improvements in density, thickness, and wrinkle metrics with topical application [2]. Anti-senescence: the 2024 He/Mazzola/Ladiges work found GHK reversed age-associated fibroblast changes in vitro, restoring the cellular phenotype from a fibrotic/senescent state toward a functional repair state [17]. Whether this translates to systemic anti-aging effects in humans has not been established in controlled trials. Formulation note: GHK-Cu activity is pH-sensitive (optimal near pH 7) and is reduced by high concentrations of ascorbic acid, which reduces the copper ion. Published formulation literature documents this incompatibility [4]. ## BPC-157 Mechanism of Action BPC-157 (body protection compound 157) is a synthetic 15-amino-acid sequence derived from a sequence in human gastric juice protein. It has been studied across tissue types with three primary proposed mechanisms. **Nitric oxide pathway.** BPC-157 disrupts the Caveolin-1/eNOS inhibitory complex in endothelial cells, releasing endothelial nitric oxide synthase and increasing NO production approximately 1.35-fold [5]. In isolated aortic ring experiments, BPC-157 produced concentration-dependent vasodilation at 100 µg/mL of approximately 48.3% relaxation [5]. Nitric oxide production mediates vascular repair and anti-inflammatory effects downstream. **FAK-paxillin fibroblast migration.** BPC-157 markedly increased fibroblast migration in a dose-dependent manner in rat tendon fibroblast cultures, with corresponding dose-dependent increases in FAK and paxillin phosphorylation [6]. The FAK-paxillin pathway governs focal adhesion dynamics and cell motility. The same study found BPC-157 accelerated outgrowth of rat tendon explants and increased fibroblast survival under oxidative stress. **Growth hormone receptor upregulation.** BPC-157 dose- and time-dependently increased growth hormone receptor expression at both mRNA and protein levels in tendon fibroblasts; pretreatment enhanced growth hormone-stimulated JAK2 signaling and fibroblast proliferation [8]. This suggests a potential mechanism for augmenting endogenous GH-mediated repair responses. **Achilles tendon model.** In transected rat Achilles tendons, BPC-157 significantly accelerated healing: improved biomechanical load capacity, Achilles functional index scores, increased fibroblasts and collagen formation, reduced inflammation, and smaller defect size with complete integrity by day 14 [7]. **Systematic review findings.** A 2025 systematic review of 36 studies (35 preclinical, 1 clinical) found BPC-157 consistently supports angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide pathway modulation across muscle, tendon, ligament, bone, and GI tissue; reduced inflammatory cytokines and improved microvascular integrity were reproducible findings [9]. **Organ protection.** BPC-157 at 20 µg/kg IP significantly reduced multi-organ histological damage (liver, kidney, lung) following lower-extremity ischemia-reperfusion in rats, with improved antioxidant markers TAS and PON-1 [10]. **Caveats.** The majority of BPC-157 preclinical literature originates from a single research group (Sikiric/Seiwerth, University of Zagreb). Independent replication is limited. Human data is confined to small pilot studies and case reports as of 2026. ## BPC-157 + TB-500 Combination Research Limited published data evaluates BPC-157 and TB-500 as a combined protocol. BPC-157 is studied primarily via VEGFR2 and nitric oxide pathways; TB-500 via G-actin sequestration and VEGF upregulation. The pathways are mechanistically complementary — both promote angiogenesis, albeit through different upstream signals — and no published study has identified antagonism. A 2026 review found BPC-157 demonstrates consistent analgesic and multi-tissue repair effects; a 2025 systematic review in HSS Journal confirmed reproducible musculoskeletal repair findings [12, 9]. TB-500's wound re-epithelialization and hair growth effects have been documented independently [13, 14, 15]. Combination trial data is sparse as of 2026. ## GHK-Cu Combination Research: Compatibility With Other Peptides GHK-Cu is predominantly studied as a standalone compound. Combination protocols with BPC-157 and TB-500 as in the GLOW blend are referenced in practitioner literature but lack published RCT data. No known mechanistic antagonism between the three compounds has been identified in the published literature. GHK-Cu and NAD+ have non-overlapping mechanisms: GHK-Cu operates via copper-regulated gene expression, NAD+ via sirtuin/PARP/ATP pathways. No published data evaluates the combination. GHK-Cu is incompatible with high concentrations of ascorbic acid in formulations due to copper reduction chemistry [4]. ## GLOW Peptide Stack: How the Constituent Compounds Interact The published mechanistic profiles of GHK-Cu, BPC-157, and TB-500 address tissue repair from three distinct molecular entry points. GHK-Cu acts upstream at the transcriptional level: modulating ECM gene networks and copper-dependent enzyme systems that set the regenerative baseline [1]. BPC-157 activates mid-level repair signaling: VEGFR2 angiogenesis, eNOS nitric oxide production, and FAK-paxillin fibroblast migration [5, 6]. TB-500 acts at the cytoskeletal and immediate wound-closure level: G-actin sequestration enabling rapid keratinocyte and endothelial cell migration, plus VEGF upregulation for local angiogenesis [13, 15]. The mechanistic complementarity is documented but not yet tested as a designed combination in any published controlled trial. The term 'synergy' is not supported by current published evidence; 'complementary non-overlapping mechanisms' is the accurate characterization. For published dosing ranges across the three constituents, read [GLOW peptide dosage](/dosage). ## Peptide Mechanisms in Skin Aging Research Signal peptides such as GHK-Cu trigger fibroblast production of collagen and glycosaminoglycans via receptor-mediated gene expression changes; enzyme-inhibitor peptides modulate metalloproteinases. These mechanisms are well established in vitro and supported by a growing preclinical literature [1, 2, 3, 4]. In vitro, GHK-Cu upregulates COL1A1, COL3A1, and elastin while maintaining MMP/TIMP balance — the ECM production vs. degradation equilibrium that determines net matrix density [1, 4]. In human photoaged skin, these in vitro signals translated to measurable improvements in skin density, reduced wrinkle depth, and improved laxity in a 12-week trial [2]. TB-500 extends this picture to wound re-epithelialization: keratinocyte migration in culture increased 2–3-fold at minimal concentrations [13], consistent with its G-actin sequestration mechanism accelerating cytoskeletal remodeling in migrating cells. ## Is GHK-Cu Peptide Really Anti-Aging? GHK-Cu studies report upregulation of collagen I, III, and elastin in fibroblast models; Pickart's foundational research demonstrates broad gene expression effects including antioxidant and anti-inflammatory gene activation [1, 2, 3]. In a human trial, 12-week topical GHK-Cu improved measurable skin parameters in photoaged women [2]. In aged fibroblasts in vitro, GHK reversed senescence-associated markers and restored functional repair phenotype [17]. Whether these effects constitute meaningful anti-aging outcomes in humans requires larger controlled trials with clinical endpoints. The mechanistic and small-trial evidence is consistent. Large-scale RCTs have not been conducted. --- Three signals monitored from the peer-reviewed record — not a clinic, not a vendor, not a reading that prescribes.